allopurinol / Generic mfg. - LARVOL DELTA

Miliary palmoplantar gout tophi in a patient with hyperuricemia and chronic renal insufficiency (PubMed, Dermatologie (Heidelb)) - "We diagnosed miliary gout (MG) and initiated uric acid-reducing therapy with allopurinol 100 mg/day. First described in 2007, MG presenting with multiple whitish-yellowish papules is a rare intradermal variant of classic gout that is characterized by subcutaneous deposits. Clinically, MG can be confused with other dermatoses, for example, cutaneous calcification or pustular palmoplantar psoriasis."

Journal • Chronic Kidney Disease • Dermatology • Gout • Immunology • Inflammatory Arthritis • Nephrology • Psoriasis • Renal Disease • Rheumatology

Thiopurine Metabolite Monitoring in Children With ALL/LLy: A Retrospective Analysis (ASPHO 2025) - "Metabolites were drawn in the majority of patients for a variety of reasons. Altered metabolism and allopurinol initiation was observed almost exclusively in patients with TMPT normal phenotypes, and allopurinol efficiently reduced 6MMPN/6TGN ratios. We also observed substantial 6MMPN, 6TGN, and ratio variation over time in patients who were not started on allopurinol, suggesting mercaptopurine metabolism may be dynamic and repeat metabolites should be considered if concerns arise."

Retrospective data • Acute Lymphocytic Leukemia • Gastrointestinal Disorder • Hepatology • Metabolic Disorders • Pediatrics • NUDT15

Chromene flavanones from Dalea boliviana as xanthine oxidase inhibitors: in vitro biological evaluation and molecular docking studies. (PubMed, Front Pharmacol) - "Compounds 1 and 2 exhibited potent inhibition, with IC50 values in the nanomolar range (0.5 ± 0.01 nM and 1.7 ± 0.46 nM, respectively), demonstrating significantly higher activity than allopurinol (AL), the reference inhibitor (IC50 = 247 ± 4 nM)...Further molecular dynamics simulations could provide deeper insights into their stability and interaction dynamics, aiding in the rational design of more effective XO inhibitors. Our findings lead us to propose these chromene flavanones as lead compounds for the design and development of novel XO inhibitors for treating diseases in which exacerbated activity of this enzyme is involved."

Journal • Preclinical • Gout • Inflammatory Arthritis • Rheumatology

Recent Progression and Treatment Approaches for the Kidney Stone Management. (PubMed, Curr Drug Targets) - "To implement more effective treatments, it is necessary to identify and develop a targeted therapy for the druggable targets. Various such druggable targets have been reported such as osteopontin which has come out as a protein with various functions including involvement in the inhibition of crystal adherence to the renal epithelium. Another such target is vitamin D and nephrocalcin."

Journal • Nephrology • Renal Calculi • Urolithiasis • SPP1

Purine xanthine oxidase inhibitors are not conducive to the prognosis of chronic heart failure: a meta-analysis. (PubMed, Eur J Clin Pharmacol) - "Purine XOI exposure may be unfavorable for the prognosis of CHF patients and is affected by the frequency and dose of use."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

Comparison of the anti-hyperuricemia effects of several cinnamic acid derivatives. (PubMed, J Sci Food Agric) - "These findings underscore the potential of naturally derived polyphenolics as promising candidates for the management of hyperuricemia, providing a safer alternative to conventional therapies."

Journal

Evaluation of clinical features and treatment modality of pediatric patients with Steven Johnson syndrome/toxic epidermal necrolysis: a single-center experience. (PubMed, Turk J Med Sci) - "Eight patients had antibiotics, two had proton pump inhibitors, two had allopurinol, and two had antiepileptic (lamotrigine and valproic acid) use. Primary treatment is supportive care. Early initiation of cyclosporine may have a positive effect on the prognosis in patients with SJS/TEN overlap and TEN."

Journal • Retrospective data • Critical care • Dermatology • Immunology • Pediatrics • Steven-Johnson Syndrome

Evaluation of Real-World Treatment Patterns and Healthcare Resource Utilization in Patients with Chronic Refractory Gout in the United States. (PubMed, Adv Ther) - "Despite the use of urate-lowering medications, patients with CRG had elevated serum urate levels and high HRU, underscoring the need for better treatment and management strategies for CRG to prevent gout flares and minimize long-term damage."

HEOR • Journal • Real-world evidence • Gout • Inflammatory Arthritis • Rheumatology

Paederia scandens extract alleviates obesity via modulating the gut microbiota and serum metabolome disorder. (PubMed, Front Microbiol) - "Serum metabolomics analysis implicated L-ascorbic acid, stevioside, allopurinol, and gingerol, along with amino acid and energy metabolism pathways, in the anti-obesity mechanism of PS. These results provide novel theoretical insights into the therapeutic potential of PS for obesity prevention and treatment."

Journal • Dyslipidemia • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • Pain

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout (clinicaltrials.gov) - P2 | N=80 | Active, not recruiting | Sponsor: InventisBio Co., Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Gout • Inflammatory Arthritis • Rheumatology

Predicting the risk of severe cutaneous adverse reactions in new allopurinol users: development and validation of a multivariable prediction model using linked primary care, hospitalisation, and mortality data from England (EULAR 2025) - No abstract available

Clinical

Allopurinol associated cardiovascular risk and protective effect of colchicine in gout patients: a Dutch nationwide pharmaco-epidemiologic cohort study. (EULAR 2025) - No abstract available

Clinical • Cardiovascular • Gout • Inflammatory Arthritis • Rheumatology

Bullous Fixed Drug Eruption to Metformin : A case report (ESPE-ESE 2025) - "All of these cases are more than 40 years of age and the lower limb is the most prevalent involved location. In our study, the occurrence of FDE following the reintroduction of metformin despite a chronic use may be explained by immune system sensitization secondary to the recent DRESS syndrome induced by allopurinol."

Case report • Clinical • Late-breaking abstract • Dermatology • Diabetes • Eosinophilia • Lichen Planus • Metabolic Disorders • Pain • Type 2 Diabetes Mellitus • Vasculitis

Allopurinol-Induced Severe Cutaneous Adverse Reactions in the Elderly: A Case Series. (ESPE-ESE 2025) - "Allopurinol is one of the most frequently implicated drugs in SCARs, with a higher prevalence in the elderly due to its widespread use in this population. DRESS syndrome is the most common reaction. Although the prognosis is relatively good, it is crucial to avoid allopurinol use in asymptomatic hyperuricemia and to enhance clinical vigilance to prevent these potentially fatal complications."

Clinical • Late-breaking abstract • Eosinophilia • Gout • Inflammatory Arthritis • Rheumatology • Steven-Johnson Syndrome

Linking Acquired Perforating Dermatosis to Diabetes and Renal Failure: A Case Report (ESPE-ESE 2025) - "APD is an underrecognized condition associated with systemic diseases like diabetes and chronic renal failure. It presents with pruritic, hyperkeratotic papules or umbilicated nodules, often on extensor surfaces. Pathogenesis may involve microtrauma, diabetic microangiopathy, or renal failure-related substance accumulation."

Case report • Clinical • Late-breaking abstract • Cardiovascular • Chronic Kidney Disease • Dermatology • Diabetes • Endocrine Disorders • Metabolic Disorders • Nephrology • Pruritus • Pulmonary Arterial Hypertension • Renal Disease

Transforming Lives: The Impact of Liver Transplantation in Treating Glycogen Storage Disease Type 1a – A Case Report (ESPE-ESE 2025) - "His triglyceride levels, despite a low triglyceride diet and the use of gemfibrozil 600 mg twice daily, ranged from 700 to 1600 mg/dl. Furthermore, his uric acid level remained elevated at 6.5 mg/dl despite being on daily allopurinol therapy (300 mg)...In cases where metabolic control cannot be adequately achieved, early liver transplantation should be considered. Further research is necessary to explore and refine treatment strategies for rare metabolic disorders like GSD type 1a."

Case report • Clinical • Cardiovascular • Dyslipidemia • Hepatocellular Cancer • Hepatology • Hypertension • Hypertriglyceridemia • Hypoglycemia • Liver Failure • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • Transplantation

Treatment of hyperuricemia as an option for slowing the progression of diabetic nephropathy (ESPE-ESE 2025) - "Our aim is to evaluate allopurinol effects on proteinuria in diabetic patients with nephropathy...Conclusions – Treatment with hyperuricemia can reduce severity of proteinuria. So, it’s important to use them as an adjuvants cost-effective therapy for patients with diabetic nephropathy."

Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects. (PubMed, Clin Pharmacol Ther) - "While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence-based recommendations exist for a subset of supportive care drugs and anticancer drugs, including thiopurines, irinotecan, capecitabine, and 5-fluorouracil...These include dose and treatment recommendations for allopurinol, nonsteroidal anti-inflammatory drugs, phenytoin, amitriptyline, proton pump inhibitors, voriconazole, tramadol, codeine, paroxetine, tacrolimus, rasburicase, and 6-mercaptopurine...Leveraging genetic profiles to guide clinicians in drug selection and dose optimization can improve patient outcomes by enhancing the safety and efficacy of treatments. We therefore recommend incorporating pharmacogenetic screening into clinical workflows to advance personalized medicine in pediatric oncology."

Biomarker • Journal • Oncology • Pediatrics

Serum Concentrations of IL-18, IL-21, IL-22, IL-23, IL-27, and IL-31 in Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Their Correlation With Disease Severity. (PubMed, Med Arch) - "The most frequently identified medications were traditional medicine (19 patients; 31.15%), allopurinol (9 patients; 14.75%), and carbamazepine (8 patients; 13.11%). Additionally, serum concentrations of IL-18, IL-27, and IL-31 were associated with disease severity as indicated by the lesional area. These interleukins may play an important role in the pathogenesis of SJS/TEN."

Biomarker • Journal • Steven-Johnson Syndrome • IL18 • IL21 • IL22 • IL23A

Pharmacovigilance and Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN): 55 Years of Retrospective Analysis of the FDA Adverse Event Reporting System (FAERS) Database. (PubMed, Hosp Pharm) - "The most frequently implicated drugs were Lamotrigine (9.17% of cases), Sulfamethoxazole/Trimethoprim (6.12%), and Allopurinol (5.88%). Other significant drugs included Phenytoin (5.05%), Acetaminophen (4.97%), and Ibuprofen (4.13%)...These findings emphasize the importance of monitoring high-risk drugs, such as antiepileptics, analgesics, and antibacterials, and implementing strategies to mitigate associated risks. This study underscores the need for ongoing surveillance and education to enhance patient safety."

Adverse events • Journal • Retrospective data • Pain • Steven-Johnson Syndrome

Steven Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) Complicated by Extensive Subcutaneous Emphysema, Pneumomediastinum, and Acute Respiratory Distress Syndrome (ATS 2025) - "Culprit drugs include nonsteroidal anti-inflammatory drugs, allopurinol, antiepileptics, and antibiotics...He received Vancomycin and Piperacillin/tazobactam, then he was transitioned to Cefepime...The culprit antibiotics were stopped, and he received IV Methylprednisolone...Documented cases of subcutaneous emphysema, pneumomediastinum, and ARDS are rare. Physician awareness will prompt early diagnosis and treatment."

Acute Kidney Injury • Acute Respiratory Distress Syndrome • Anemia • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Septic Shock • Steven-Johnson Syndrome

Diffuse Large B-cell Lymphoma Presenting as Dysphagia and Respiratory Symptoms (ATS 2025) - "He was treated with mini R-CHOP therapy (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab), tenofovir for HBV prophylaxis, and allopurinol to prevent tumor lysis syndrome. Ann Oncol. 2000; 11(Suppl 3): 219-222."

Anemia • B Cell Lymphoma • Cardiovascular • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • Diffuse Large B Cell Lymphoma • Esophageal Cancer • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatitis C • Hepatology • Immunology • Infectious Disease • Lymphoma • Nephrology • Non-Hodgkin’s Lymphoma • Oncology • Pain • Renal Disease • Respiratory Diseases • BCL2 • BCL6 • CD20 • MME • PAX5 • PTPRC

Long-term cardiovascular safety of febuxostat compared with allopurinol or no urate-lowering treatment in people with gout: a cohort study in UK primary care using the Clinical Practice Research Datalink. (BSR 2025) - "Febuxostat does not appear to increase the risk of major CV adverse events when used as ULT for patients with gout compared with not receiving ULT. These findings provide reassurance about using febuxostat in people with gout."

Clinical • Cardiovascular • Congestive Heart Failure • Dyslipidemia • Gout • Heart Failure • Inflammatory Arthritis • Ischemic stroke • Myocardial Infarction • Rheumatology

Advances in Crystal Arthritis (BSR 2025) - "Attendees will learn about recent evidence for two therapeutic issues in crystal arthritis: (1) the approach to managing hard to treat crystal arthritis with biological and non-biological drugs and (2) the cardiovascular risks and benefits associated with gout therapies (including allopurinol, febuxostat and colchicine). The emerging role of Dual Energy CT (DECT) for assessment and diagnosis of crystal arthritis will also be highlighted. Aim To provide an update on topical issues in crystal arthritis Outcome 1 To be aware of the evidence for the effectiveness of non-biologic and biologic drugs to treat crystal arthritis Outcome 2 To learn about the role of dual energy CT in the diagnosis of crystal arthritis Outcome 3 To understand the latest evidence of the cardiovascular benefits associated with gout therapies"

Cardiovascular • Gout • Immunology • Inflammatory Arthritis • Rheumatology

An infographic for commencing allopurinol therapy (BSR 2025) - "There is no abstract associated with this presentation."

Immunology • Rheumatology